Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753201 | 0.79 | SCN2A (0.44) | SCN2ALMNATSHRCYP3A4ALDH1A1 | |
| SCHEMBL25753161 | 0.78 | SCN2A (0.43) | SCN2ALMNATSHRCYP3A4ALDH1A1 | |
| SCHEMBL25753214 | 0.77 | MAPT (0.39) | LMNACYP3A4ALDH1A1KMT2APKM | |
| SCHEMBL25753149 | 0.69 | HTT (0.50) | SCN2ALMNATSHRCYP3A4ALDH1A1 | |
| SCHEMBL25753216 | 0.68 | GAA (0.36) | SCN2ALMNATSHRCYP3A4ALDH1A1 | |
| SCHEMBL26126512 | 0.66 | ESR1 (0.42) | SCN2AALDH1A1POLBKMT2ARECQL | |
| SCHEMBL16698918 | 0.65 | SCN2A (0.46) | SCN2ALMNACYP3A4ALDH1A1POLB | |
| SCHEMBL3583148 | 0.61 | SCN2A (0.47) | SCN2ALMNACYP3A4ALDH1A1POLB | |
| SCHEMBL16620361 | 0.60 | MEN1 (0.36) | LMNATSHRCYP3A4ALDH1A1KMT2A | |
| SCHEMBL1973251 | 0.57 | SCN2A (1.00) | SCN2ALMNAALDH1A1ARKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | SQLE, HCCS, DHPS | SCN2A 4538/4885LMNA 2236/4885TSHR 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.